Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPB2 | Q96IY4 | 15/20 | 0.44 |
| ▸ | CPB1 | P15086 | 6/20 | 0.43 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.35 |
| ▸ | KDM5A | P29375 | 1/20 | 0.33 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14551478 | 0.84 | CPB2 (0.39) | CPB2CPB1 | |
| SCHEMBL27803087 | 0.82 | CPB2 (0.53) | CPB2CPB1LPAR1KDM5AKDM5B | |
| SCHEMBL14551467 | 0.81 | CPB2 (0.40) | CPB2CPB1 | |
| SCHEMBL27803207 | 0.79 | CPB2 (0.55) | CPB2CPB1LPAR1KDM5AKDM5B | |
| SCHEMBL1441194 | 0.78 | CPB2 (0.50) | CPB2CPB1LPAR1 | |
| SCHEMBL14789440 | 0.78 | CPB2 (0.43) | CPB2CPB1 | |
| SCHEMBL7256341 | 0.78 | CPB2 (0.50) | CPB2CPB1LPAR1 | |
| SCHEMBL27803083 | 0.77 | CPB2 (0.54) | CPB2CPB1KDM5AKDM5B | |
| SCHEMBL27781569 | 0.77 | CPB2 (0.54) | CPB2CPB1KDM5AKDM5B | |
| SCHEMBL14790054 | 0.76 | CPB2 (0.41) | CPB2CPB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9662310-B2 | Cyclopropanecarboxylic acid derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2017-05-30 | — | — | US | disclosed |
| EP-2548872-B1 | CYCLOPROPANECARBOXYLIC ACID DERIVATIVE | DAIICHI SANKYO CO LTD (JP) | 2016-09-28 | — | — | EP | disclosed |
| US-8946443-B2 | Cyclopropanecarboxylic acid derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2015-02-03 | — | — | US | disclosed |
| EP-2548872-A1 | CYCLOPROPANECARBOXYLIC ACID DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-01-23 | — | — | EP | disclosed |
| US-20130012532-A1 | CYCLOPROPANECARBOXYLIC ACID DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130012532-A1 | CYCLOPROPANECARBOXYLIC ACID DERIVATIVE | TFPI, TFPI2, TAF11 | CPB2 13/4885CPB1 8/4885LPAR1 2800/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.